Synthesis and Characterization of Paclitaxel-Loaded PEGylated Liposomes by the Microfluidics Method.
cancer
chemotherapy
liposomes
microfluidics
nanomedicine
paclitaxel
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
medline:
5
12
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
ppublish
Résumé
For cancer therapy, paclitaxel (PX) possesses several limitations, including limited solubility and untargeted effects. Loading PX into nanoliposomes to enhance PX solubility and target their delivery as a drug delivery system has the potential to overcome these limitations. Over the other conventional method to prepare liposomes, a microfluidic system is used to formulate PX-loaded PEGylated liposomes. The impact of changing the flow rate ratio (FRR) between the aqueous and lipid phases on the particle size and polydispersity index (PDI) is investigated. Moreover, the effect of changing the polyethylene glycol (PEG) lipid ratio on the particle size, PDI, stability, encapsulation efficiency % (EE %), and release profile is studied. The physicochemical characteristics of the obtained formulation were analyzed by dynamic light scattering, FTIR spectroscopy, and AFM. This work aims to use microfluidic technology to produce PEGylated PX-loaded liposomes with a diameter of <200 nm, low PDI < 0.25 high homogeneity, and viable 28 day stability. The results show a significant impact of FRR and PEG lipid ratio on the empty liposomes' physicochemical characteristics. Among the prepared formulations, two formulations produce size-controlled, low PDI, and stable liposomes, which make them preferable for PX encapsulation. The average EE % was >90% for both formulations, and the variation in the PEG lipid ratio affected the EE % slightly; a high packing for PX was reported at different drug concentrations. A variation in the release profiles was notified for the different PEG lipid ratios.
Identifiants
pubmed: 37931072
doi: 10.1021/acs.molpharmaceut.3c00596
pmc: PMC10698720
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Liposomes
0
Polyethylene Glycols
3WJQ0SDW1A
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6184-6196Références
Int J Pharm. 2022 Nov 25;628:122320
pubmed: 36272514
Pharmaceutics. 2019 Nov 14;11(11):
pubmed: 31739556
Medchemcomm. 2019 Feb 12;10(3):369-377
pubmed: 31015904
J Pharm Sci. 1995 Dec;84(12):1464-77
pubmed: 8748330
Expert Opin Drug Deliv. 2016 Sep;13(9):1257-75
pubmed: 27116988
Nanoscale Res Lett. 2011 Aug 03;6(1):482
pubmed: 21812989
Biochim Biophys Acta. 2012 Nov;1818(11):2801-7
pubmed: 22766474
Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1238-44
pubmed: 12237543
Prog Lipid Res. 2005 Jan;44(1):68-97
pubmed: 15748655
Artif Cells Nanomed Biotechnol. 2018;46(sup1):684-692
pubmed: 29475393
Int J Pharm. 2007 Jun 29;338(1-2):317-26
pubmed: 17368984
Front Mol Biosci. 2020 Aug 20;7:193
pubmed: 32974385
Langmuir. 2019 May 7;35(18):6048-6054
pubmed: 30991806
J Pharm Pharmacol. 2023 Feb 8;75(2):245-252
pubmed: 36453867
J Pharm Sci. 2013 Jan;102(1):227-36
pubmed: 23132529
Pharmaceutics. 2022 Apr 02;14(4):
pubmed: 35456613
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Pharmaceutics. 2020 Oct 22;12(11):
pubmed: 33105650
J Control Release. 2012 Nov 10;163(3):322-34
pubmed: 22989535
ISRN Pharmacol. 2012;2012:623139
pubmed: 22934190
Nanomedicine (Lond). 2013 Sep;8(9):1509-28
pubmed: 23914966
Nature. 1993 Jul 29;364(6436):464-6
pubmed: 8101355
Drug Deliv Transl Res. 2015 Jun;5(3):231-42
pubmed: 25787731
Anal Bioanal Chem. 2017 Sep;409(24):5779-5787
pubmed: 28762066
Int J Pharm. 2019 Jul 20;566:687-696
pubmed: 31212051
Int J Oncol. 2018 Sep;53(3):1105-1117
pubmed: 29956746
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
Nanomaterials (Basel). 2021 Dec 18;11(12):
pubmed: 34947789
J Control Release. 2022 Feb;342:280-294
pubmed: 35016919
Int J Nanomedicine. 2006;1(3):297-315
pubmed: 17717971
Drug Deliv. 2007 Jul;14(5):301-8
pubmed: 17613018
Int J Pharm. 2008 Apr 2;353(1-2):251-9
pubmed: 18191511
ACS Macro Lett. 2020 Sep 15;9(9):1292-1302
pubmed: 35638634
Int J Pharm. 2002 Mar 20;235(1-2):179-92
pubmed: 11879753
J Liposome Res. 2010 Sep;20(3):228-43
pubmed: 19899957
Biomed Pharmacother. 2021 Jan;133:111059
pubmed: 33378963
Colloids Surf B Biointerfaces. 2015 Jul 1;131:54-8
pubmed: 25950496
Langmuir. 2019 May 7;35(18):6064-6074
pubmed: 30977658
Int J Pharm. 2018 Jan 30;536(1):95-107
pubmed: 29175440
Int J Nanomedicine. 2010 Mar 09;5:101-8
pubmed: 20309396
Iran J Pharm Res. 2014 Winter;13(Suppl):3-14
pubmed: 24711824
Int J Pharm. 2015 May 15;485(1-2):122-30
pubmed: 25725309
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):524-539
pubmed: 30784319
J Pharm Pharmacol. 2011 Jan;63(1):80-6
pubmed: 21155819
Int J Nanomedicine. 2019 Jul 11;14:5159-5173
pubmed: 31371954
Int J Pharm. 2022 Jan 5;611:121347
pubmed: 34890709
Pharmaceutics. 2022 Nov 16;14(11):
pubmed: 36432675
Acta Pharm Sin B. 2020 Sep;10(9):1730-1740
pubmed: 33088692
J Therm Anal Calorim. 2022;147(11):6337-6348
pubmed: 34220293
Pharm Dev Technol. 2018 Jan;23(1):76-86
pubmed: 28724327
Biophys J. 2012 Feb 8;102(3):507-16
pubmed: 22325273
J Control Release. 2019 Aug 10;307:211-220
pubmed: 31170464
Drug Deliv Transl Res. 2019 Feb;9(1):404-413
pubmed: 30306459
RSC Adv. 2018 Jul 2;8(43):24084-24093
pubmed: 35539172
J Colloid Interface Sci. 2006 Aug 1;300(1):314-26
pubmed: 16603177
Chem Phys Lipids. 2005 Jun;135(2):117-29
pubmed: 15921973
Molecules. 2022 Feb 06;27(3):
pubmed: 35164350